| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $385.2M | — | +8.6% |
| R&D Expense | $24.6M | — | -9.4% |
| SG&A Expense | $53.5M | — | -18.5% |
| Operating Income | $33.5M | — | +340.1% |
| Pre-tax Income | $3.3M | — | +108.5% |
| Income Tax | $1.1M | — | -49.0% |
| Net Income | $2.2M | — | +105.3% |
| EPS (Basic) | $0.01 | — | +104.2% |
| EPS (Diluted) | $0.01 | — | +104.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $225.9M | -5.9% | +31.3% |
| Accounts Receivable | $287.7M | -3.2% | +8.1% |
| Current Assets | $539.3M | -4.0% | +14.3% |
| Total Assets | $3.75B | -2.1% | -3.0% |
| Current Liabilities | $203.5M | -11.7% | -15.6% |
| Long-term Debt | $2.06B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $49.4M | — | +153.9% |
| Capital Expenditures | $2.8M | — | +479.8% |
| Investing Cash Flow | -$14.0M | — | -26.5% |
| Financing Cash Flow | -$44.3M | — | -638.5% |
| Free Cash Flow | $46.6M | — | +145.5% |
| -4.7% |
| Total Liabilities | $2.46B | -2.4% | -5.1% |
| Stockholders' Equity | $1.29B | -1.5% | +1.2% |